我武生物(300357) - 2021 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2021 reached ¥272,116,595.68, representing a year-over-year increase of 17.48%[5] - Net profit attributable to shareholders was ¥127,276,283.26, up 4.26% compared to the same period last year[5] - The net profit after deducting non-recurring gains and losses was ¥125,588,217.73, reflecting a 10.17% increase year-over-year[5] - Total operating revenue for the current period reached ¥619,721,426.61, an increase of 26.2% compared to ¥491,058,886.79 in the previous period[30] - Net profit for the current period was ¥266,294,363.50, representing a 19.2% increase from ¥223,376,917.75 in the previous period[33] - The company reported a total profit of ¥320,968,916.49, which is a 20.6% increase from ¥265,996,849.31 in the previous period[33] - Basic earnings per share for the current period were ¥0.5244, compared to ¥0.4376 in the previous period, reflecting a growth of 19.8%[37] Cash Flow - Cash flow from operating activities amounted to ¥242,046,010.16, showing a 26.51% increase from the beginning of the year[5] - Cash flow from operating activities generated ¥564,509,773.24, an increase from ¥457,394,693.03 in the previous period[38] - Operating cash inflow totaled CNY 597,623,360.81, an increase of 22.4% compared to CNY 488,077,643.62 in the previous period[41] - Cash outflow from operating activities was CNY 355,577,350.65, up from CNY 296,750,411.43, resulting in a net cash flow from operating activities of CNY 242,046,010.16, an increase of 26.5%[41] - Cash inflow from investment activities reached CNY 578,541,929.36, compared to CNY 309,978,793.06, marking an increase of 86.6%[41] - Cash outflow from investment activities was CNY 735,139,051.92, significantly higher than CNY 365,238,079.30, leading to a net cash flow from investment activities of CNY -156,597,122.56[41] - Cash flow from financing activities resulted in a net outflow of CNY -89,862,925.67, compared to CNY -94,245,120.00 in the previous period[44] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,853,615,234.67, a 15.51% increase from the previous year[7] - The company's equity attributable to shareholders increased to ¥1,666,004,937.21, marking a 14.43% rise year-over-year[7] - The total liabilities of the company as of September 30, 2021, were RMB 89,793,384.44, compared to RMB 55,419,690.55 in the previous year[25] - Total liabilities reached ¥123,669,634.97, an increase of 61.5% from ¥76,607,698.67 in the previous period[29] - The total current liabilities were 55,419,690.55, reflecting a decrease from 60,881,547.98[51] - The non-current liabilities totaled 21,188,008.12, down from 25,905,218.01[51] Investments and Expenses - Research and development expenses rose by ¥16,414,616.51, an increase of 36.89%, driven by ongoing investments in existing projects[9] - Research and development expenses increased to ¥60,905,616.89, a rise of 37.0% compared to ¥44,491,000.38 in the previous period[33] - Zhejiang WoWo Biotechnology invested RMB 43.45 million in Shanghai Kaiyi Pharmaceutical Technology Co., Ltd. to support its operational and long-term funding needs[19] - The registered capital of Kaiyi Pharmaceutical increased from RMB 260.107 million to RMB 316.615 million after the investment, with Zhejiang WoWo's ownership rising from 19.905% to 35.021%[19] Other Financial Metrics - The weighted average return on net assets was 8.04%, a decrease of 1.04 percentage points compared to the previous year[5] - The company received government subsidies totaling ¥13,262,221.63 during the reporting period[8] - Deferred income increased to ¥25,035,133.36 from ¥20,630,680.00, indicating a growth of 21.7%[29] - The company reported a cash and cash equivalents balance of CNY 216,616,892.70 at the end of the period, down from CNY 191,638,285.30[44] - The company received CNY 560,000,000.00 from investment recoveries, significantly up from CNY 308,000,000.00[41] - The company paid CNY 170,589,965.13 to employees, an increase from CNY 117,772,149.72, indicating a focus on workforce investment[41] Reporting and Compliance - The report for the third quarter of 2021 was not audited, indicating a potential area for further scrutiny[55] - The company has implemented new leasing standards effective from January 1, 2021, impacting asset and liability recognition[54]